RIVAL - Valuation & Licensing Software for Biopharma

Rival is a value management software platform that allows you to model the value and licensing terms of your pipeline assets.

Trusted by leading
pharma & biotech companies

Find out how we can serve your needs

Book a free consultation with one of our specialists

Book your free consultation

What can you achieve using RIVAL?

With RIVAL you will be able to communicate the value of your efforts to all stakeholders, manage risks and turn your R&D work into a successful financial outcome.

Quantify the value of your pipeline & monitor the development over time
Perform sensitivity analysis on key value drivers (time, risk, free cash flow)
Model the value of existing or future licensing contracts
Compare your valuation with similar private or public companies
Get access to curated partners or investors

75%

Average time savings

+25%

Average improvement
licensing deal terms

100%

Error reduction

Curated investor
matches

5-10

Financing comparables

How the platform works

Asset Value Modelling

The software allows you to model the value of your asset per indication and geography and provides guidance on the different input parameters and bench-marking data. This output is visualized in clear and insightful graphics and allows for sensitivity analysis of key value drivers.

Portfolio Value Management

View the status of multiple projects on a single timeline in a snapshot and grow your ROI. Cross-portfolio visibility saves valuable time, increases decision-making accuracy, and keeps everyone aligned.

Licensing Deal Simulation

The Licensing Deal Module allows for licensing deal terms simulation and optimization. The clear visualizations provide powerful insights in the value split between parties, breakdown of the allocated economics and bench-marking of the deal terms

Discover how RIVAL will support your funding efforts

Book a free consultation with one of our specialists

Book your free consultation

RIVAL is a core tool for our company. The flexibility to build valuation models quickly allows for broad and informative analyses, and enables us to optimize our strategic planning activities and decision making. Overall, RIVAL contributes substantially to business development and strategy at Kura Oncology

Ryan Snyder

Executive Director Business Development

Portfolio management and understanding asset valuation are natural next steps when it comes to developing a well-rounded project manager in the biopharmaceutical space. RIVAL is an ideal tool to facilitate the growth of my team in these areas as it offers a user-friendly, low barrier to entry experience, without sparing on high-quality outputs to effectively manage our programs.

Nathan Wheeler MPH, PMP

Associate Vice President, Project & Portfolio Management

Why choose RIVAL?

An easy-to-access platform that puts it all at your fingertips

RIVAL is the premier resource for comprehensive pharma and biotech valuations, sensitivity analysis, portfolio management, license deal modelling, generating insights designed to empower your best business decisions

Avance has served over 450 clients and supported USD 10B+ deal value

Based on the Book written by Avance team “Valuation in Life Sciences”. That is the textbook used by INSEAD, Wharton and Harvard Business School

Trained more than 2,500 life sciences professionals on 4 continents through our valuation courses

We work with a pool of highly experienced executives from top-tier companies in the industry (e.g. Roche/Novartis/BMS/Novo Nordisk etc.)

Contact Us

Enter you details and book a free consultation with our team

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.